Research indicates that while statins and PCSK9 inhibitors effectively lower cholesterol, their medical and economic value remains a subject of intense debate. Statins are proven to reduce cardiovascular mortality in high-risk patients, yet evidence suggests they are associated with an increased risk of new-onset diabetes, particularly at higher intensities. Despite this metabolic risk, clinical guidelines generally maintain that the cardiovascular benefits of statin therapy outweigh the potential for glycemic disruption. Regarding newer treatments, an economic evaluation found that PCSK9 inhibitors are currently not cost-effective for the U.S. health system due to their high annual price. For these drugs to provide a positive return on investment for private payers and the broader society, significant price reductions of over 70% would be required. Overall, the complex balance between clinical efficacy, patient safety, and the financial sustainability of long-term cardiovascular interventions.